发明公开
EP2564834A3 Compounds for Proteasome Enzyme Inhibition
审中-公开
Verbindungen zur Proteasomenzyminhibition
- 专利标题: Compounds for Proteasome Enzyme Inhibition
- 专利标题(中): Verbindungen zur Proteasomenzyminhibition
-
申请号: EP12189466.1申请日: 2005-05-09
-
公开(公告)号: EP2564834A3公开(公告)日: 2013-08-21
- 发明人: Smyth, Mark S. , Laidig, Guy J. , Borchardt, Ronald T. , Binin, Barry A. , Crews, Craig M. , Musser, John H. , Shenk, Kevin D. , Radel, Peggy A.
- 申请人: Onyx Therapeutics, Inc.
- 申请人地址: 249 East Grand Avenue South San Francisco, CA 94080 US
- 专利权人: Onyx Therapeutics, Inc.
- 当前专利权人: Onyx Therapeutics, Inc.
- 当前专利权人地址: 249 East Grand Avenue South San Francisco, CA 94080 US
- 代理机构: Carlisle, Julie
- 优先权: US569885P 20040510; US610040P 20040914; US634366P 20041207
- 主分类号: A61K9/19
- IPC分类号: A61K9/19 ; A61K31/336 ; A61K31/396 ; A61K47/40 ; A61K9/00 ; C07K5/062
摘要:
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
公开/授权文献
- EP2564834A2 Compounds for Proteasome Enzyme Inhibition 公开/授权日:2013-03-06
信息查询